Evofem Biosciences, Inc. Quarterly Debt-to-equity in % from Q3 2018 to Q2 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Evofem Biosciences, Inc. quarterly Debt-to-equity history and growth rate from Q3 2018 to Q2 2024.
  • Evofem Biosciences, Inc. Debt-to-equity for the quarter ending June 30, 2024 was -109 %, a 22.4% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q2 2024 -109 +31.6 +22.4% Jun 30, 2024
Q1 2024 -114 +20.7 +15.4% Mar 31, 2024
Q4 2023 -125 +6.13 +4.69% Dec 31, 2023
Q3 2023 -132 -0.82 -0.63% Sep 30, 2023
Q2 2023 -141 -3.78 -2.75% Jun 30, 2023
Q1 2023 -135 +51.8 +27.7% Mar 31, 2023
Q4 2022 -131 +153 +53.9% Dec 31, 2022
Q3 2022 -131 +580 +81.5% Sep 30, 2022
Q2 2022 -137 -1.19K -113% Jun 30, 2022
Q1 2022 -187 -554 -151% Mar 31, 2022
Q4 2021 -283 -519 -220% Dec 31, 2021
Q3 2021 -711 -843 -637% Sep 30, 2021
Q2 2021 1.05K +951 +956% Jun 30, 2021
Q1 2021 367 +288 +362% Mar 31, 2021
Q4 2020 236 +67.9 +40.5% Dec 31, 2020
Q3 2020 132 -1.08K -89.1% Sep 30, 2020
Q2 2020 99.5 +489 Jun 30, 2020
Q1 2020 79.5 +264 Mar 31, 2020
Q4 2019 168 +384 Dec 31, 2019
Q3 2019 1.21K +1.27K Sep 30, 2019
Q2 2019 -390 Jun 30, 2019
Q1 2019 -185 Mar 31, 2019
Q4 2018 -217 Dec 31, 2018
Q3 2018 -56.6 Sep 30, 2018
* An asterisk sign (*) next to the value indicates that the value is likely invalid.